Opthea Stock

Opthea EBIT

The EBIT of Opthea (OPT.AX) as of Jul 7, 2026 is -155.88 T USD.In the previous year, EBIT was -191.98 T USD — a change of -18.8% (higher).

EBIT

-155.88 TUSD

YoY

-18.8%

Last updated:

In 2026, Opthea's EBIT was -155.88 T USD, a -18.8% increase from the -191.98 T USD EBIT recorded in the previous year.

The Opthea EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2006
-3.61 base
Jan 1, 2007
12.8 base
Jan 1, 2008
-0.85 base
Jan 1, 2009
-8.12 base
Jan 1, 2010
-8.57 base
Jan 1, 2011
-10.09 base
Jan 1, 2012
-7.72 base
Jan 1, 2013
-7 base
Jan 1, 2014
-6.72 base
Jan 1, 2015
-8.45 base
Jan 1, 2016
-5.07 base
Jan 1, 2017
-6.34 base
Jan 1, 2018
-19.57 base
Jan 1, 2019
-25 base
Jan 1, 2020
-17.09 base
YEAREBIT (M USD)
2031 est -
2030 est -
2029 est 56.7
2028 est -5.98
2027 est -4.85
2026 est -4.85
2025 -155.88
2024 -191.98
2023 -150.3
2022 -96.65
2021 -39.67
2020 -17.09
2019 -25
2018 -19.57
2017 -6.34
2016 -5.07
2015 -8.45
2014 -6.72
2013 -7
2012 -7.72
2011 -10.09
2010 -8.57
2009 -8.12
2008 -0.85
2007 12.8
2006 -3.61
Access this data via the Eulerpool API

Opthea Revenue

Opthea Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
1.17 M USD
-3.61 M USD
-6.47 M USD
Jan 1, 2007
29.89 M USD
12.8 M USD
11.2 M USD
Jan 1, 2008
8.15 M USD
-850,000 USD
-1.15 M USD
Jan 1, 2009
3.09 M USD
-8.12 M USD
-9.92 M USD
Jan 1, 2010
2.27 M USD
-8.57 M USD
-6.95 M USD
Jan 1, 2011
1.83 M USD
-10.09 M USD
-10.27 M USD
Jan 1, 2012
1.49 M USD
-7.72 M USD
-4.84 M USD
Jan 1, 2013
1.15 M USD
-7 M USD
-4.75 M USD
Jan 1, 2014
880,000 USD
-6.72 M USD
-4 M USD
Jan 1, 2015
939,000 USD
-8.45 M USD
-5.31 M USD
Jan 1, 2016
530,000 USD
-5.07 M USD
-4.51 M USD
Jan 1, 2017
390,100 USD
-6.34 M USD
-4.21 M USD
Jan 1, 2018
778,100 USD
-19.57 M USD
-11.5 M USD
Jan 1, 2019
108,200 USD
-25 M USD
-14.23 M USD
Jan 1, 2020
59,100 USD
-17.09 M USD
-11.12 M USD

Opthea Margins

Opthea stock margins

The Opthea margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Opthea. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Opthea.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
64.96 %
-308.55 %
-552.99 %
Jan 1, 2007
66.81 %
42.82 %
37.47 %
Jan 1, 2008
76.07 %
-10.43 %
-14.11 %
Jan 1, 2009
34.3 %
-262.78 %
-321.04 %
Jan 1, 2010
48.9 %
-377.53 %
-306.17 %
Jan 1, 2011
61.2 %
-551.37 %
-561.2 %
Jan 1, 2012
-3.36 %
-518.12 %
-324.83 %
Jan 1, 2013
46.96 %
-608.7 %
-413.04 %
Jan 1, 2014
35.23 %
-763.64 %
-454.55 %
Jan 1, 2015
63.29 %
-899.41 %
-565.72 %
Jan 1, 2016
54.47 %
-956.53 %
-850.4 %
Jan 1, 2017
55.09 %
-1,626.4 %
-1,079.98 %
Jan 1, 2018
77.42 %
-2,514.97 %
-1,477.78 %
Jan 1, 2019
-72.27 %
-23,104.07 %
-13,147.04 %
Jan 1, 2020
-504.06 %
-28,911.68 %
-18,820.98 %

Opthea Stock analysis

What does Opthea do? Opthea Ltd is a biopharmaceutical company specializing in the development of novel therapies for various eye diseases. The company was founded in 1985 in Melbourne, Australia as a spin-off from the Burnet Institute for Medical Research and Public Health. Since then, Opthea has become a leading company in ophthalmology and is researching innovative therapies that have the potential to improve the lives of millions of patients worldwide. Opthea's business model is to develop novel therapies for various eye diseases and market these therapies through partnerships with established pharmaceutical companies. The company focuses on developing therapies based on the inhibition of growth factors and other signaling pathways that promote the development of abnormal blood vessels and inflammation. This therapeutic principle offers a promising way to effectively treat various eye diseases. Opthea specializes in developing therapies for the treatment of wet age-related macular degeneration (AMD), which is the leading cause of severe visual impairment in older people. Opthea is developing a therapy aimed at inhibiting the excessive formation of blood vessels in the macula of the eye, which can impair vision. The drug called OPT-302 is used in combination therapies with existing treatments for wet AMD and has the potential to slow down the progression of the disease and improve vision. In addition to the therapy for wet AMD, Opthea is also researching therapy options for other eye diseases such as diabetic retinopathy, retinal vein occlusion, and corneal diseases. Opthea has filed numerous patents in this field and collaborates with various academic and clinical partners to advance the development of innovative therapies. Another important component of Opthea's business model is collaboration with established pharmaceutical companies. In 2020, Opthea entered into a licensing agreement with the pharmaceutical company Novartis, which includes exclusive distribution and marketing rights for the drug OPT-302 in Europe, Japan, and other countries outside of North America. This partnership allows Opthea to benefit from collaboration with an experienced and established partner while maximizing the potential of its innovative therapy. In summary, Opthea is a promising company in ophthalmology that specializes in the development of innovative therapies for various eye diseases. The company works closely with academic and clinical partners and leverages the advantages of partnerships with established pharmaceutical companies to maximize the potential of its therapies. With the therapy for wet AMD already in the pipeline, Opthea is expected to develop further therapy options in the future that will contribute to improving the lives of millions of patients worldwide. Opthea is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Opthea's EBIT

Opthea's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Opthea's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Opthea's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Opthea’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Opthea stock

EBIT of Opthea amounted to -191.98 T USD -155.88 T

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Opthea

All Key Metrics — Opthea